Macrophage ITGAV is dispensable for post-infarction remodeling in mice and does not mediate fibronectin responses Authors: Ruoshui Li, Shuaibo Huang, Anis Hanna, Silvia C. Hernandez, Akihiko Kubota, Claudio Humeres, Izabela Tuleta, Nikolaos G. Frangogiannis Published: 2025 ABSTRACT Macrophages sense changes in their matrix environment through the integrins. In vitro, αV integrin (ITGAV) has been suggested to modulate a broad range of macrophage responses. However, the in vivo role of macrophage ITGAV in injury and repair remains unknown. Here we use myeloid cell and macrophage-specific ITGAV knockout mice and in vitro experiments to investigate the role of ITGAV signaling in repair and remodeling after myocardial infarction. ScRNA-sequencing and immunofluorescence show that ITGAV mRNA and protein are highly expressed in infarct macrophage subpopulations. Myeloid cell-specific and macrophage-specific loss of ITGAV have no significant effects on post-infarction remodeling and dysfunction and do not significantly affect macrophage recruitment, myofibroblast infiltration, collagen deposition and angiogenesis in the infarcted heart. In vitro, RNA-sequencing shows that the ITGAV activator fibronectin, which is abundantly expressed in healing infarcts, has profound effects on the macrophage transcriptome, inducing inflammatory, cell cycle and extracellular matrix proteolysis genes. These effects are independent of ITGAV. In conclusion, macrophage ITGAV does not play an important role in regulating repair, remodeling and fibrosis in a mouse model of myocardial infarction. The lack of functional impact may be attributed to the limited role of ITGAV in transducing fibronectin-mediated signals in macrophages. Introduction Adult mammals have negligible cardiac regenerative capacity. Following myocardial infarction, cessation of blood flow in the area perfused by the occluded vessel results in sudden death of up to a billion cardiomyocytes overwhelming any endogenous mechanisms of remuscularization. Thus, repair of the infarcted heart is dependent on sequential recruitment and activation of immune and reparative cells that ultimately results in formation of a collagen-based scar1. Timely activation and suppression of inflammatory and reparative pathways protects the infarcted heart from catastrophic complications (such as ventricular rupture) and attenuates adverse remodeling and post-infarction heart failure. Macrophages are central effector cells in repair and remodeling of the infarcted heart2,3,4,5,6, playing crucial roles in regulation of cellular processes in all phases of infarct healing7. During the inflammatory phase, macrophages respond to alarmins released by dead cells, by secreting cytokines and chemokines, thus stimulating recruitment of pro-inflammatory leukocytes8,9,10. Activation of a phagocytic macrophage phenotype clears the infarct from dead cells and matrix fragments11, setting the stage for generation of a reparative environment. As macrophages ingest apoptotic cells, they acquire an anti-inflammatory profile and contribute to suppression12 and resolution of post-infarction inflammation13,14. Moreover, subpopulations of infarct macrophages stimulate fibroblast activation and expansion by secreting fibrogenic growth factors, and regulate angiogenesis15–19. The diverse functions of infarct macrophages in phagocytosis, regulation of inflammation, fibrosis, angiogenesis and matrix remodeling reflect both their heterogeneity, and their capacity to sense changes in their microenvironment and undergo dramatic phenotypic transitions20,21. Macrophages express a wide range of sensor molecules on their surface that convey information on the presence of stress or tissue injury. These sensors serve to identify neighboring cells or matrix components, to detect pathogens, or to respond to metabolites, bioactive mediators and damage-associated molecular patterns. Mechanical cues from the extracellular matrix are transduced through the integrins, a family of heterodimeric surface receptors that bind to matrix ligands and activate downstream signaling cascades22–24. Integrins are heterodimers, comprised of non-covalently interacting combinations of one α and one β subunit. The large extracellular domain of each subunit binds the matrix ligands, whereas the short cytoplasmic tail transmits mechanical forces through cytoskeletal linker molecules25, but can also transduce biochemical signaling cascades that elicit or modulate a wide range of cellular responses, including motility, proliferation, and differentiation. Integrin αv (ITGAV) is highly expressed in macrophages, in vitro26 and in vivo27,28. A large body of in vitro evidence suggests an important role for ITGAV in regulating macrophage phenotype. ITGAV expression has been associated with monocyte to macrophage differentiation29. Moreover, in vitro experiments have suggested that ITGAV may modulate macrophage inflammatory activation, promoting an M2-like phenotype30, by regulating cytokine synthesis and release31,32, and by locally activating TGF-β33. In vivo evidence on the role of macrophage ITGAV is much more limited. Cell-specific loss-of-function approaches have suggested that myeloid cell ITGAV is implicated in immune intestinal homeostasis through effects attributed to generation of mucosal regulatory T cells (Tregs)34. However, the in vivo role of macrophage ITGAV in tissue injury, repair and remodeling remains unknown. In the current study, we tested the hypothesis that macrophage ITGAV plays a central role in regulation of macrophage function in the infarcted and remodeling myocardium. We demonstrated that Itgav is broadly expressed in infarct macrophage populations. However, in vivo studies using 2 different Cre drivers showed that myeloid cell- and macrophage-specific ITGAV signaling has no significant effects on repair, myofibroblast accumulation, angiogenesis and remodeling after myocardial infarction. Moreover, ITGAV blockade in vitro had modest effects on the macrophage transcriptome and did not affect the induction of inflammatory, matrix remodeling and cell cycle genes induced by fibronectin stimulation. The absence of significant effects of ITGAV loss on post-infarction cardiac function and remodeling may be attributed to its limited role in transducing fibronectin-derived signals. Results Expression of Itgav and its partner chains Itgb1 and Itgb5 in infarct macrophages In healing infarcts, macrophages exhibit remarkable heterogeneity. To examine whether various subpopulations of macrophages have distinct expression profiles of Itgav and its partner β chains, we analyzed published RNA-seq data reporting gene expression profiles of interstitial cells infiltrating the infarcted myocardium35. In order to facilitate interpretation of the data in relation to published observations, we used the same dimensionality reduction that identified 8 distinct monocyte/macrophage clusters, as described in the original publication by Farbehi et al.35: MAC-TR cardiac resident macrophages, M1-like macrophages with evidence of inflammatory activation, M1-like monocytes (M1Mo), M2-like macrophages exhibiting an anti-inflammatory/reparative profile, interferon-activated cells (MAC-IFNIC) and 3 minor subpopulations Mac6, Mac7 and Mac8 (Fig. 1A–D). Itgav was expressed in subpopulations of macrophages from all clusters (Fig. 1E–H) in both sham and infarction groups. In sham heart macrophages Itgav was expressed at significantly lower levels in the Mac-TR cluster of macrophages, in comparison to all other clusters (Fig. 1I). MAC-TR cells are a subpopulation of resident macrophages that exhibit high levels of CX3CR1 and F4/80, but low CCR2 expression. After 3 days of infarction, Itgav expression was higher in M1-like macrophages, in comparison to all other macrophage clusters (Fig. 1K). At the 7-day timepoint, M2 macrophages had significantly higher Itgav levels than all other clusters (Fig. 1L). In contrast, at both 3- and 7-day timepoints, M1 monocytes had lower Itgav expression than other myeloid cell subpopulations. Overall, Itgav is expressed by subpopulations of infarct macrophages without a consistent association with specific clusters.Fig. 1Cluster-specific patterns of expression of Itgav in infarct macrophages.We analyzed published scRNA-seq data35 on the transcriptional profile of infarct interstitial cells in a mouse model of non-reperfused myocardial infarction. Panels A–D show the monocyte-macrophage clusters, as these were identified by the authors in the original study and the numbers of cells in sham mice (B) and in 3- and 7-day infarcts (C–D). E–H Feature plots show that Itgav is expressed in subsets of cells from all clusters in both sham and infarction groups. I–L Violin plots show Itgav expression in macrophage clusters in sham and infarcted hearts. In sham cardiac macrophages Itgav was expressed at lower levels in the TR cluster of macrophages, in comparison to all other clusters (J). M1-like macrophages (M1Mac) had higher Itgav expression, in comparison to all other macrophage clusters 3 days after infarction (K), whereas at the 7-day timepoint, M2-like macrophages (M2Mac) had significantly higher Itgav levels (L). (**p < 0.01, ***p < 0.001, ****p < 0.0001). Statistical analysis was performed using differential expression testing in Seurat V5 package, utilizing Wilcoxon rank sum test followed by Bonferroni correction for multiple comparisons. Cluster-specific patterns of expression of Itgav in infarct macrophages. We analyzed published scRNA-seq data35 on the transcriptional profile of infarct interstitial cells in a mouse model of non-reperfused myocardial infarction. Panels A–D show the monocyte-macrophage clusters, as these were identified by the authors in the original study and the numbers of cells in sham mice (B) and in 3- and 7-day infarcts (C–D). E–H Feature plots show that Itgav is expressed in subsets of cells from all clusters in both sham and infarction groups. I–L Violin plots show Itgav expression in macrophage clusters in sham and infarcted hearts. In sham cardiac macrophages Itgav was expressed at lower levels in the TR cluster of macrophages, in comparison to all other clusters (J). M1-like macrophages (M1Mac) had higher Itgav expression, in comparison to all other macrophage clusters 3 days after infarction (K), whereas at the 7-day timepoint, M2-like macrophages (M2Mac) had significantly higher Itgav levels (L). (**p < 0.01, ***p < 0.001, ****p < 0.0001). Statistical analysis was performed using differential expression testing in Seurat V5 package, utilizing Wilcoxon rank sum test followed by Bonferroni correction for multiple comparisons. Of the 5 ITGAV partners (ITGB1, ITGB3, ITGB5, ITGB6 and ITGB8), Itgb1 is broadly expressed by macrophages in sham and infarcted hearts (Supplementary Fig. 1). In sham heart macrophages, there were no significant differences in Itgb1 expression between clusters (Supplementary Fig. 1I). 3 days after infarction, M1 macrophages and the Mac8 cluster (one of the minor myeloid cell clusters) exhibited higher Itgb1 expression levels than all other clusters (Supplementary Fig. 1J). 7 days after infarction, only the Mac8 cluster had significantly higher expression of Itgb1 (Supplementary Fig. 1K). In contrast, at both 3 and 7-day timepoints M1 monocytes and the Mac6 clusters had significantly lower Itgb1 levels than other clusters (Supplementary Fig. 1J–K). Itgb5 was also highly expressed in cardiac macrophages (Supplementary Fig. 2A–E) and was significantly induced in macrophages after infarction (7-day MI vs sham macrophages: avglog2FC = 0.69, p < 0.0001). In sham, 3-day and 7-day myeloid cells, Itgb5 expression was higher in M2 macrophages, in comparison to all other clusters (M2 macrophages vs all other clusters: avglogFC= 1.23, p < 0.0001). In contrast, M1 monocytes and the Mac6, Mac7 and Mac8 clusters exhibited lower Itgb5 expression (M1 monocytes: avglogFC = −1.82, p < 0.0001; Mac6: avglogFC = −1.26, p < 0.0001; Mac7: avglogFC = −1.5, p < 0.0001; Mac8: avglogFC = −0.7, p < 0.0006, vs all other clusters). Expression of Itgb3 was very low in macrophages of all clusters and at all timepoints (Supplementary Fig. 2F–J). Negligible Itgb6 and Itgb8 expression was noted in cardiac myeloid cells at all timepoints studied. Time course of ITGAV expression in infarct macrophages Next, we examined the time course of infiltration of the infarct with ITGAV+ macrophages. To identify macrophages in control and infarcted hearts, we used CSF1REGFP reporter mice. Immunofluorescent staining showed marked infiltration of the infarcted heart with CSF1R+ macrophages that peaked 7 days after coronary occlusion (Fig. 2A–B). Dual fluorescence showed infiltration of the infarct with ITGAV+ macrophages 3 days after coronary occlusion, followed by a marked increase in the density of ITGAV + /CSF1R+ cells 7 days after coronary occlusion (Fig. 2D). The density of ITGAV-expressing macrophages was somewhat reduced during the maturation phase of infarct healing, reflecting the smaller macrophage population found at this timepoint. At both 7- and 28-day timepoints, ~10-15% of CSF1R+ cells infiltrating the infarct exhibited ITGAV immunoreactivity (Fig. 2E).Fig. 2Time course of ITGAV expression in infarct macrophages.Dual immunofluorescence in myocardial sections from CSF1REGFP macrophage reporter mice was used to localize ITGAV immunoreactivity in macrophages from control hearts and in myocardial infarcts during the inflammatory (24h-3 days), proliferative (7 days) and maturation phase (28 days) of infarct healing. A–B Control (Con) mouse hearts had a small population of CSF1R+ macrophages cells (arrows), that did not exhibit significant ITGAV immunoreactivity. 24h-3 days after MI, large numbers of CSF1R+ macrophages were identified in the infarcted myocardium (arrows). A relatively small fraction of these cells expressed ITGAV. Numerous ITGAV + /CSF1R+ macrophages (arrowheads) were noted 7 days after infarction (7dI). The density of ITGAV + CSF1R+ macrophages was reduced at the 28-day timepoint (28 d I). Images in column B represent magnified fields from the respective images in column A. C Quantitative analysis showed that density of CSF1R+ macrophages infiltrating the infarcted myocardium significantly increased after 3 days and peaked 7 days after MI. No significant increase in the density of myeloid cells was noted in non-infarcted remodeling (R) segments. D Increased density of ITGAV+ macrophages was noted 7-28 days after infarction. E ~10–20% of infarct macrophages expressed ITGAV at the 7 and 28-day timepoints. Scale bar=50μm (column A). Scale bar=25 μm (column B) (*p < 0.05, **p < 0.01, ***p < 0.001 vs. C; ^p < 0.05, ^^^p < 0.001 vs. corresponding remote non-infarcted myocardium, n = 6/group). Statistical analysis was performed using the Kruskal-Wallis test followed by Dunn’s multiple comparisons test. Data are expressed as mean ± SEM. Time course of ITGAV expression in infarct macrophages. Dual immunofluorescence in myocardial sections from CSF1REGFP macrophage reporter mice was used to localize ITGAV immunoreactivity in macrophages from control hearts and in myocardial infarcts during the inflammatory (24h-3 days), proliferative (7 days) and maturation phase (28 days) of infarct healing. A–B Control (Con) mouse hearts had a small population of CSF1R+ macrophages cells (arrows), that did not exhibit significant ITGAV immunoreactivity. 24h-3 days after MI, large numbers of CSF1R+ macrophages were identified in the infarcted myocardium (arrows). A relatively small fraction of these cells expressed ITGAV. Numerous ITGAV + /CSF1R+ macrophages (arrowheads) were noted 7 days after infarction (7dI). The density of ITGAV + CSF1R+ macrophages was reduced at the 28-day timepoint (28 d I). Images in column B represent magnified fields from the respective images in column A. C Quantitative analysis showed that density of CSF1R+ macrophages infiltrating the infarcted myocardium significantly increased after 3 days and peaked 7 days after MI. No significant increase in the density of myeloid cells was noted in non-infarcted remodeling (R) segments. D Increased density of ITGAV+ macrophages was noted 7-28 days after infarction. E ~10–20% of infarct macrophages expressed ITGAV at the 7 and 28-day timepoints. Scale bar=50μm (column A). Scale bar=25 μm (column B) (*p < 0.05, **p < 0.01, ***p < 0.001 vs. C; ^p < 0.05, ^^^p < 0.001 vs. corresponding remote non-infarcted myocardium, n = 6/group). Statistical analysis was performed using the Kruskal-Wallis test followed by Dunn’s multiple comparisons test. Data are expressed as mean ± SEM. Myeloid cell-specific loss of ITGAV does not affect mortality, dysfunction, and adverse remodeling after myocardial infarction To study the role of ITGAV in regulation of macrophage phenotype following infarction, we generated mice with myeloid cell-specific ITGAV loss using the LyzM Cre driver (MyαVKO). MyαVKO animals had no baseline defects. Following myocardial infarction, MyαVKO mice and corresponding Itgav fl/fl controls had comparable mortality in both male and female groups (Supplementary Fig. 3). Macrophage-specific loss of ITGAV in MyαVKO mice was documented using western blotting and dual immunofluorescence. Western blotting showed that bone marrow macrophages harvested from MyαVKO mice had markedly reduced ITGAV levels, in comparison to macrophages harvested from Itgav fl/fl controls (Fig. 3A–B, Supplementary Fig. 4). Moreover, the density of CD68 + /ITGAV+ macrophages was markedly reduced in infarcted MyαVKO mice when compared to ITGAV fl/fl infarcts, reflecting macrophage-specific ITGAV loss (Supplementary Fig. 5). Echocardiographic analysis showed that MyαVKO mice and ITGAV fl/fl controls had comparable left ventricular dysfunction and dilative remodeling 7–28 days after coronary occlusion (Fig. 3C–E). Sex-specific analysis of the effects of myeloid cell-specific ITGAV loss on post-infarction left ventricular dysfunction and dilative remodeling is shown in Supplementary Fig. 6.Fig. 3Myeloid cell-specific ITGAV loss does not affect post-infarction remodeling.Representative images of western blots (A), followed by quantitative analysis (B) show that bone-marrow macrophages isolated from MyαVKO mice have markedly reduced ITGAV expression. After infarction both ITGAV fl/fl and MyαVKO exhibited a marked reduction in ejection fraction (C), accompanied by increased LVEDV (D) and LVESV (E). Myeloid cell-specific loss of ITGAV did not affect systolic dysfunction and dilative remodeling at both 7-day and 28-day timepoints. (**p < 0.01; ^^p < 0.01, ^^^p < 0.001, ^^^^p < 0.0001 vs corresponding pre-infarction mice. ITGAV fl/fl pre: n = 18; MyαVKO pre: n = 21; ITGAV fl/fl 7 d: n = 7; MyαVKO 7 d: n = 9; ITGAV fl/fl 28 d: n = 10; MyαVKO 28 d: n = 12 – n = number of biologically independent animals). Statistical analysis was performed using an unpaired two-tailed Student’s t-test for comparisons between two groups (B), and a one-way ANOVA followed by Sidak’s multiple comparisons test for comparisons among multiple groups (C–E). Data are expressed as mean ± SEM. Myeloid cell-specific ITGAV loss does not affect post-infarction remodeling. Representative images of western blots (A), followed by quantitative analysis (B) show that bone-marrow macrophages isolated from MyαVKO mice have markedly reduced ITGAV expression. After infarction both ITGAV fl/fl and MyαVKO exhibited a marked reduction in ejection fraction (C), accompanied by increased LVEDV (D) and LVESV (E). Myeloid cell-specific loss of ITGAV did not affect systolic dysfunction and dilative remodeling at both 7-day and 28-day timepoints. (**p < 0.01; ^^p < 0.01, ^^^p < 0.001, ^^^^p < 0.0001 vs corresponding pre-infarction mice. ITGAV fl/fl pre: n = 18; MyαVKO pre: n = 21; ITGAV fl/fl 7 d: n = 7; MyαVKO 7 d: n = 9; ITGAV fl/fl 28 d: n = 10; MyαVKO 28 d: n = 12 – n = number of biologically independent animals). Statistical analysis was performed using an unpaired two-tailed Student’s t-test for comparisons between two groups (B), and a one-way ANOVA followed by Sidak’s multiple comparisons test for comparisons among multiple groups (C–E). Data are expressed as mean ± SEM. Myeloid cell-specific ITGAV loss does not affect scar remodeling following infarction Next, we examined whether myeloid cell-specific ITGAV loss affects scar remodeling after non-reperfused myocardial infarction. Infarcted hearts were sectioned from base to apex after 7 and 28 days of coronary occlusion (Fig. 4A), and the entire ventricle was reconstructed using morphometric techniques, as previously described36. Both MyαVKO and ITGAV fl/fl infarcts exhibited replacement of dead myocardium with scar 7 days after coronary occlusion, reflecting comparable phagocytic removal of dead myocardium and formation of granulation tissue (Fig. 4). An increase in the volume of non-infarcted viable myocardium was noted 28 days after infarction, in comparison to the 7-day timepoint, reflecting hypertrophic remodeling of the myocardium (Fig. 4B). In contrast, the volume of the infarct and the size of the infarct (expressed as a percentage of the total ventricular volume) were reduced at the 28-day timepoint, reflecting scar contraction (Fig. 4C–D). Myeloid cell-specific ITGAV loss did not affect the volume of the infarcted and non-infarcted myocardium and the size of the scar after 7 or 28 days of coronary occlusion (Fig. 4B–D).Fig. 4Myeloid cell-specific ITGAV loss does not affect infarct size and scar remodeling after non-reperfused myocardial infarction.A To assess scar size after 7–28 days of coronary occlusion, systematic quantification of morphometric parameters was performed by sectioning and staining the entire heart from base to apex. Representative images of H&E-stained sections are shown, and the area of replacement fibrosis is traced at each level. B–D The volume of the viable myocardium increased in both MyαVKO and ITGAV fl/fl mice 28 days after MI, when compared to the 7-day timepoint, reflecting progressive hypertrophy of non-infarcted segments (B). In contrast, the volume of the infarct (C), and the size of the scar (expressed as a percentage of the left ventricular volume, D) were decreased at the 28-day timepoint, in comparison to 7-day infarcts, reflecting scar contraction. No significant differences were noted in the volume of the viable myocardium (B), infarct volume (C) and infarct size (D) between MyαVKO mice and corresponding ITGAV fl/fl at both 7-day and 28-day timepoints. Scalebar=2 mm. (^p < 0.05, ^^p < 0.01, ^^^p < 0.001, ^^^^p < 0.0001 vs. corresponding 7-day infarction timepoint (ITGAV fl/fl 7 d: n = 8, MyαVKO 7 d: n = 9, ITGAV fl/fl 28 d: n = 9, MyαVKO 28 d: n = 11 - n = number of biologically independent animals). Statistical analysis was performed using a one-way ANOVA followed by Sidak’s multiple comparisons test for comparisons among multiple groups. Data are expressed as mean ± SEM. Myeloid cell-specific ITGAV loss does not affect infarct size and scar remodeling after non-reperfused myocardial infarction. A To assess scar size after 7–28 days of coronary occlusion, systematic quantification of morphometric parameters was performed by sectioning and staining the entire heart from base to apex. Representative images of H&E-stained sections are shown, and the area of replacement fibrosis is traced at each level. B–D The volume of the viable myocardium increased in both MyαVKO and ITGAV fl/fl mice 28 days after MI, when compared to the 7-day timepoint, reflecting progressive hypertrophy of non-infarcted segments (B). In contrast, the volume of the infarct (C), and the size of the scar (expressed as a percentage of the left ventricular volume, D) were decreased at the 28-day timepoint, in comparison to 7-day infarcts, reflecting scar contraction. No significant differences were noted in the volume of the viable myocardium (B), infarct volume (C) and infarct size (D) between MyαVKO mice and corresponding ITGAV fl/fl at both 7-day and 28-day timepoints. Scalebar=2 mm. (^p < 0.05, ^^p < 0.01, ^^^p < 0.001, ^^^^p < 0.0001 vs. corresponding 7-day infarction timepoint (ITGAV fl/fl 7 d: n = 8, MyαVKO 7 d: n = 9, ITGAV fl/fl 28 d: n = 9, MyαVKO 28 d: n = 11 - n = number of biologically independent animals). Statistical analysis was performed using a one-way ANOVA followed by Sidak’s multiple comparisons test for comparisons among multiple groups. Data are expressed as mean ± SEM. Myeloid cell-specific loss of ITGAV does not affect macrophage infiltration in the infarcted heart Next, we examined whether ITGAV plays a role in recruitment of macrophages in the infarcted myocardium. Immunofluorescence for the macrophage marker Mac2 was used to compare macrophage density in the infarcted and remote remodeling myocardial segments between MyαVKO and control ITGAV fl/fl mice (Supplementary Fig. 7A). No significant differences in macrophage accumulation were noted after 7–28 days of coronary occlusion (Supplementary Fig. 7B). Myeloid cell-specific loss of ITGAV does not significantly affect infiltration of the infarct with α-SMA+ myofibroblasts Macrophages play an important role in regulating myofibroblast activation in the healing infarct through secretion of fibrogenic growth factors and matricellular proteins. To examine the effects of myeloid cell ITGAV loss on infiltration of the infarcted heart with myofibroblasts, we performed α-SMA immunofluorescence. Myofibroblasts were identified as α-SMA-immunoreactive cells located outside the vascular media (Fig. 5A). After 7 days of coronary occlusion, myofibroblast density was ~20% lower in MyαVKO infarcts, when compared with ITGAV fl/fl controls, however this difference did not reach statistical significance (p = 0.072, Fig. 5B). After 28 days of coronary occlusion, MyαVKO mice and ITGAV fl/fl controls had comparable infarct myofibroblast density (Fig. 5B).Fig. 5Myeloid cell specific ITGAV loss does not significantly affect myofibroblast density in healing infarcts.Infarct myofibroblasts (arrows) were identified in ITGAV fl/fl and in MyαVKO infarcts (A) as α-smooth muscle actin (α-SMA)+ cells located outside the vascular media. In both Itgav fl/fl and MyαVKO infarcts, myofibroblast density peaks 7 days after coronary occlusion and is significantly decreased during scar maturation (28 days after coronary occlusion), as myofibroblasts convert to matrifibrocytes. Quantitative analysis (B) showed that MyαVKO mice had a modest ~20% reduction in peak myofibroblast density at the 7-day timepoint that did not reach statistical significance. Scalebar=100 μm. (ITGAV fl/fl 7 d: n = 8, MyαVKO 7 d: n = 9], ITGAV fl/fl 28 d: n = 9, MyαVKO 28 d: n = 10 - n = number of biologically independent animals). Statistical analysis was performed using Brown-Forsythe ANOVA for unequal variances followed by Dunnett’s T3 multiple comparisons test. Data are expressed as mean ± SEM. Myeloid cell specific ITGAV loss does not significantly affect myofibroblast density in healing infarcts. Infarct myofibroblasts (arrows) were identified in ITGAV fl/fl and in MyαVKO infarcts (A) as α-smooth muscle actin (α-SMA)+ cells located outside the vascular media. In both Itgav fl/fl and MyαVKO infarcts, myofibroblast density peaks 7 days after coronary occlusion and is significantly decreased during scar maturation (28 days after coronary occlusion), as myofibroblasts convert to matrifibrocytes. Quantitative analysis (B) showed that MyαVKO mice had a modest ~20% reduction in peak myofibroblast density at the 7-day timepoint that did not reach statistical significance. Scalebar=100 μm. (ITGAV fl/fl 7 d: n = 8, MyαVKO 7 d: n = 9], ITGAV fl/fl 28 d: n = 9, MyαVKO 28 d: n = 10 - n = number of biologically independent animals). Statistical analysis was performed using Brown-Forsythe ANOVA for unequal variances followed by Dunnett’s T3 multiple comparisons test. Data are expressed as mean ± SEM. Effects of myeloid cell-specific loss of ITGAV on infarct collagen content Next, we examined whether myeloid cell-specific ITGAV loss affects collagen content in the infarcted myocardium. Picrosirius red staining was used to label collagen fibers and to quantitatively assess collagen content in the infarcted and remote remodeling myocardium (Supplementary Fig. 8A). No significant differences in collagen content were noted between MyαVKO animals and ITGAV fl/fl mice in the infarcted and remote remodeling myocardium, after 7-28 days of coronary occlusion (Supplementary Fig. 8B). Effects of myeloid cell-specific ITGAV loss on infarct angiogenesis Macrophages are central regulators of infarct angiogenesis, acting through secretion of angiogenic cytokines and growth factors. To examine whether myeloid cell ITGAV signaling plays a role in infarct angiogenesis, we stained endothelial cells using CD31 immunohistochemistry (Fig. 6A). Quantitative analysis showed no significant effects of myeloid cell-specific ITGAV loss on the microvascular density in infarcted and remote remodeling myocardial segments (Fig. 6B).Fig. 6Myeloid cell-specific ITGAV loss does not affect microvascular density in the healing infarct.A CD31 immunohistochemistry was used to label endothelial cells. Representative images show CD31 staining of the infarcted area and remote remodeling myocardium from ITGAV fl/fl and MyαVKO mice after 7 and 28 days of coronary occlusion. B Quantitative analysis showed that MyαVKO mice and corresponding ITGAV fl/fl animals had comparable microvascular density in the infarct and in the remote remodeling myocardium. Scalebar=100 μm. (ITGAV fl/fl 7 d: n = 8, MyαVKO 7 d: n = 9, ITGAV fl/fl 28 d: n = 8, MyαVKO 28 d: n = 10 - n = number of biologically independent animals). Statistical analysis was performed using a one-way ANOVA followed by Sidak’s multiple comparisons test for comparisons among multiple groups. Data are expressed as mean ± SEM. Myeloid cell-specific ITGAV loss does not affect microvascular density in the healing infarct. A CD31 immunohistochemistry was used to label endothelial cells. Representative images show CD31 staining of the infarcted area and remote remodeling myocardium from ITGAV fl/fl and MyαVKO mice after 7 and 28 days of coronary occlusion. B Quantitative analysis showed that MyαVKO mice and corresponding ITGAV fl/fl animals had comparable microvascular density in the infarct and in the remote remodeling myocardium. Scalebar=100 μm. (ITGAV fl/fl 7 d: n = 8, MyαVKO 7 d: n = 9, ITGAV fl/fl 28 d: n = 8, MyαVKO 28 d: n = 10 - n = number of biologically independent animals). Statistical analysis was performed using a one-way ANOVA followed by Sidak’s multiple comparisons test for comparisons among multiple groups. Data are expressed as mean ± SEM. Macrophage-specific ITGAV loss does not affect post-infarction remodeling Our experiments using the LyzM-Cre driver showed no significant effects of myeloid cell-specific ITGAV in post-infarction dysfunction and dilative remodeling. Although the LyzM-Cre driver is very effective for myeloid cell-specific loss-of-function studies, it lacks specificity targeting not only macrophages, but also neutrophils. To examine the effects of macrophage-specific ITGAV signaling in the infarcted heart, we used the CX3CR1-CreER to generate inducible macrophage-specific ITGAV KO mice (iMaαVKO mice). In our first experiment, tamoxifen induction was performed prior to infarction. Macrophage-specific deletion of ITGAV was demonstrated using dual immunofluorescent staining for ITGAV and the macrophage marker CD68 (Supplementary Fig. 9). These mice had no baseline defects. Macrophage-specific ITGAV loss did not affect mortality (Supplementary Fig. 10), dysfunction and adverse remodeling (Supplementary Fig. 11) after myocardial infarction. Macrophage-specific ITGAV loss has no significant effects on scar size, macrophage and myofibroblast infiltration after myocardial infarction We used systematic morphometric analysis of hearts sectioned from base to apex to examine the effects of macrophage-specific ITGAV loss on the size of the infarct. Macrophage-specific ITGAV loss did not affect scar size after 7 and 28 days of coronary occlusion (Supplementary Fig. 12). Moreover, inducible macrophage-specific ITGAV loss did significantly affect macrophage density in healing infarcts, assessed through Mac2 immunofluorescence (Supplementary Fig. 13). Quantitative assessment of myofibroblast density in the infarcted myocardium using α-SMA immunofluorescence showed a modest (~20%) increase in myofibroblast density in iMaαVKO mouse infarcts, in comparison to ITGAV fl/fl controls at the 7-day timepoint that did not reach statistical significance (p = 0.095, Supplementary Fig. 14). After 28 days of coronary occlusion, no significant difference in myofibroblast density was noted (Supplementary Fig. 14). Sustained macrophage-specific ITGAV loss does not affect post-infarction remodeling Because the pre-infarction tamoxifen induction protocol may not target a significant fraction of monocyte-derived macrophages that infiltrate the infarct during the proliferative phase of cardiac repair, we also performed experiments in iMaαVKO mice induced through a dual course of tamoxifen that also included a 4-day post-MI course. Dual immunofluorescent staining showed a significant reduction in macrophage ITGAV expression 28 days after infarction (Supplementary Fig. 15). No statistically significant differences in post-infarction mortality were noted between iMaαVKO and ITGAV fl/fl controls (Fig. 7A). Moreover, the heart weight to body weight (HW:BW) and lung weight to body weight (LW:BW) ratios were comparable between groups 28 days after MI (Fig. 7B–C). Echocardiographic analysis at 7- and 28-day timepoints showed that infarcted iMaαVKO and ITGAV fl/fl controls had severe systolic dysfunction (evidenced by reduced LV ejection fraction) and dilative remodeling (evidenced by increased LVEDV and LVESV) in comparison to pre-infarction values. However, iMaαVKO and ITGAV fl/fl mice had comparable LVEF, LVEDV and LVESV 7 and 28 days after MI, suggesting that macrophage-specific ITGAV does not play an important role in post-infarction dysfunction and remodeling (Fig. 7D–I).Fig. 7Sustained macrophage-specific ITGAV loss does not affect post-infarction dysfunction and remodeling.A dual tamoxifen induction protocol (5-day course before coronary occlusion followed by a 4-day course post-MI) was used to achieve recombination in newly recruited macrophages infiltrating the infarct during the proliferative phase of repair. A No statistically significant differences in post-infarction mortality were noted between iMaαVKO and ITGAV fl/fl controls. Mortality was compared using the log-rank test (ITGAV fl/fl: n = 16, iMaαVKO: n = 18). Moreover, the heart weight to body weight (HW:BW) and lung weight to body weight (LW:BW) ratios were comparable between groups 28 days after MI (B–C) (ITGAV fl/fl: n = 13, iMaαVKO: n = 18). Echocardiographic analysis at 7- and 28-day timepoints showed that infarcted iMaαVKO and ITGAV fl/fl controls had severe systolic dysfunction (evidenced by reduced LV ejection fraction, D, G) and dilative remodeling (evidenced by increased LVEDV and LVESV, E–F, H–I) in comparison to pre-infarction values. E–I However, iMaαVKO and ITGAV fl/fl mice had comparable LVEF, LVEDV and LVESV 7 and 28 days after MI, suggesting that macrophage-specific ITGAV does not play an important role in post-infarction dysfunction and remodeling (ITGAV fl/fl pre: n = 15, iMaαVKO pre: n = 18, ITGAV fl/fl 7 d: n = 15, iMaαVKO 7 d: n = 18. 28 ITGAV fl/fl 28 d: n = 13, iMaαVKO 28 d: n = 18 - n = number of biologically independent animals). Statistical analysis was performed using the Mann–Whitney test (B–C), and the Kruskal–Wallis test followed by Dunn’s multiple comparisons test (D–I). Data are expressed as mean ± SEM. Sustained macrophage-specific ITGAV loss does not affect post-infarction dysfunction and remodeling. A dual tamoxifen induction protocol (5-day course before coronary occlusion followed by a 4-day course post-MI) was used to achieve recombination in newly recruited macrophages infiltrating the infarct during the proliferative phase of repair. A No statistically significant differences in post-infarction mortality were noted between iMaαVKO and ITGAV fl/fl controls. Mortality was compared using the log-rank test (ITGAV fl/fl: n = 16, iMaαVKO: n = 18). Moreover, the heart weight to body weight (HW:BW) and lung weight to body weight (LW:BW) ratios were comparable between groups 28 days after MI (B–C) (ITGAV fl/fl: n = 13, iMaαVKO: n = 18). Echocardiographic analysis at 7- and 28-day timepoints showed that infarcted iMaαVKO and ITGAV fl/fl controls had severe systolic dysfunction (evidenced by reduced LV ejection fraction, D, G) and dilative remodeling (evidenced by increased LVEDV and LVESV, E–F, H–I) in comparison to pre-infarction values. E–I However, iMaαVKO and ITGAV fl/fl mice had comparable LVEF, LVEDV and LVESV 7 and 28 days after MI, suggesting that macrophage-specific ITGAV does not play an important role in post-infarction dysfunction and remodeling (ITGAV fl/fl pre: n = 15, iMaαVKO pre: n = 18, ITGAV fl/fl 7 d: n = 15, iMaαVKO 7 d: n = 18. 28 ITGAV fl/fl 28 d: n = 13, iMaαVKO 28 d: n = 18 - n = number of biologically independent animals). Statistical analysis was performed using the Mann–Whitney test (B–C), and the Kruskal–Wallis test followed by Dunn’s multiple comparisons test (D–I). Data are expressed as mean ± SEM. In vitro effects of ITGAV neutralization on the transcriptional profile of bone marrow macrophages (BMM) To examine the in vitro role of ITGAV in regulation of macrophage phenotype we examined the effects of ITGAV neutralization on the transcriptional profile of BMMs, in the presence or absence of fibronectin, a potent activator of ITGAV that is abundantly expressed in healing infarcts37,38. Fibronectin stimulation resulted in profound transcriptional reprogramming of the macrophages, upregulating 1627 genes and downregulating 1355 genes (Fig. 8A). Among the top-ranked genes induced by fibronectin were key pro-inflammatory genes, such as Tnf (log2FC = 1.25, padj=8.25E-16), the pro-inflammatory activator Trem1 (log2FC = 1.14, padj=5.12E-12), and the members of the chemokine family Ccl2 (log2FC = 1.75, padj=3.69E-20), Ccl4 (log2FC = 1, padj=1.65E-12) and Ccl7 (logFC=1.79, padj=1.24E-21) (Fig. 8B). Fibronectin also upregulated genes involved in extracellular matrix proteolysis, such as Plaur (log2FC = 1.11, padj=1.13E-26) and Plau (log2FC = 1.39, padj=8.8E-19), as well as cell cycle regulators, including Ccnd1 (log2FC = 1.33, padj=3.61E-24) and Cdk18 (log2FC = 0.84, padj=3.87E-16). The top-ranked genes downregulated by fibronectin included Thbs1/Thrombospondin (TSP)-1 (log2FC = -1.22, padj=1.07E-32), and the negative regulator of inflammation Entpd1 (log2FC = -0.89, padj=4.86E-20) (Fig. 8B). Pathway enrichment analysis using IPA suggested that fibronectin stimulation may stimulate activation of canonical pathways, such as “Cell Cycle Control of Chromosomal Replication”, “Hepatic Fibrosis Signaling” and “Rho GTPAse Signaling”, while the “p53 signaling” pathway was predicted to be inhibited (Supplementary Fig. 16). Furthermore, upstream regulator analysis identified Myc, TNF and TGFB1 as putative activated transcriptional drivers of the fibronectin-mediated macrophage response (z-score>2), while p53 was predicted to be inhibited (z-score = −4.255) (Supplementary Fig. 17).Fig. 8The effects of fibronectin on the transcriptome of bone marrow macrophages (BMMs) are independent of ITGAV.A RNA-seq showed that fibronectin stimulation has profound effects on the transcriptional profile of BMMs, upregulating 1627 genes and downregulating 1355 genes. B Among the top-ranked genes induced by fibronectin were pro-inflammatory genes (including Tnf, Trem1, Ccl2, Ccl4, and Ccl7), genes involved in extracellular matrix proteolysis (Plaur and Plau), and cell cycle genes (such as Ccnd1 and Cdk18). The top-ranked genes downregulated by fibronectin included Thbs1/Thrombospondin (TSP)-1, and the inhibitor of inflammation Entpd1. C–D In cells treated with a blocking anti-ITGAV antibody, fibronectin had profound effects on the transcriptional profile of BMMs, upregulating 1756 genes and downregulated 1351 genes. Fibronectin-mediated upregulation of inflammatory, cell cycle-associated and proteolysis-related genes was independent of ITGAV. E–F The effects of ITGAV blockade on the BMM transcriptome were modest. In unstimulated cells (E), the most significantly upregulated genes were Fos, Thbs1, and Myo1e. Fos remained the top-ranked upregulated gene upon ITGAV blockade in fibronectin-stimulated BMMs (F). Statistical analysis was performed using DESeq2 R package, which employs the Wald test to calculate p-values and Log2 fold changes for differential expression analysis (n = 4/group - n = number of biologically independent experiments). The effects of fibronectin on the transcriptome of bone marrow macrophages (BMMs) are independent of ITGAV. A RNA-seq showed that fibronectin stimulation has profound effects on the transcriptional profile of BMMs, upregulating 1627 genes and downregulating 1355 genes. B Among the top-ranked genes induced by fibronectin were pro-inflammatory genes (including Tnf, Trem1, Ccl2, Ccl4, and Ccl7), genes involved in extracellular matrix proteolysis (Plaur and Plau), and cell cycle genes (such as Ccnd1 and Cdk18). The top-ranked genes downregulated by fibronectin included Thbs1/Thrombospondin (TSP)-1, and the inhibitor of inflammation Entpd1. C–D In cells treated with a blocking anti-ITGAV antibody, fibronectin had profound effects on the transcriptional profile of BMMs, upregulating 1756 genes and downregulated 1351 genes. Fibronectin-mediated upregulation of inflammatory, cell cycle-associated and proteolysis-related genes was independent of ITGAV. E–F The effects of ITGAV blockade on the BMM transcriptome were modest. In unstimulated cells (E), the most significantly upregulated genes were Fos, Thbs1, and Myo1e. Fos remained the top-ranked upregulated gene upon ITGAV blockade in fibronectin-stimulated BMMs (F). Statistical analysis was performed using DESeq2 R package, which employs the Wald test to calculate p-values and Log2 fold changes for differential expression analysis (n = 4/group - n = number of biologically independent experiments). The effects of fibronectin stimulation on expression of inflammatory, cell cycle and extracellular matrix proteolysis genes were not dependent on ITGAV. In cells treated with a neutralizing anti-ITGAV antibody, fibronectin had profound effects on the transcriptional profile of BMMs, upregulating 1756 genes and downregulated 1351 genes (Fig. 8C). Fibronectin markedly upregulated expression of inflammatory, cell cycle-related and proteolysis-associated genes and downregulated Thbs1 and Entpd1, in the presence or absence of ITGAV neutralization (Fig. 8D). The effects of ITGAV blockade on the transcriptional profile of BMMs, in the presence or absence of fibronectin were modest. In the absence of fibronectin, ITGAV blockade in cultured BMMs led to upregulation of 495 genes and downregulation of 598 genes (Supplementary Fig. 18A), of which only 29 and 6 genes respectively remained significant after adjustment for multiple comparisons using the Benjamini-Hochberg correction. Among the most significantly upregulated genes were Fos (log2FC = 0.72, padj=1.5E-05), a central component of the AP-1 complex and a key activator of pro-inflammatory macrophage signaling; Thbs1 (Thrombospondin-1) (log2FC = 0.4, padj=0.0004), a matricellular gene implicated in fibrogenic and angiostatic processes; and Myo1e, a gene involved in cytoskeletal organization (log2FC = 0.63, padj=1.59E-07) (Fig. 8E). In fibronectin-stimulated cells, the effects of ITGAV blockade were even less pronounced, resulting in upregulation of 315 genes and downregulation of 236 genes (Supplementary Fig. 18B), of which only 4 and 1 gene, respectively remained significant after correction using Benjamini-Hochberg. Fos remained the top-ranked upregulated gene upon ITGAV blockade (logFC=0.55, p = 7.15E-06, padj=0.037) (Fig. 8F). Pathway analysis using IPA suggested that the pathways “antimicrobial peptides” and “MMP inhibition” were predicted to be inhibited (z-score < -2), while “NGF-mediated transcription” and “adipogenesis” pathways were predicted to be activated. (Supplementary Fig. 19A). Importantly, several genes encoding matrix-degrading proteases, such as Mmp8, Mmp12 and Mmp13 were upregulated upon ITGAV blockade, while Timp3 was downregulated (Supplementary Fig. 19B). These findings may suggest a potential role for macrophage ITGAV signaling in regulation of matrix metabolism. Discussion Although in vitro studies have suggested a central involvement of ITGAV in regulation of macrophage phenotype and function, the in vivo role of macrophage-specific ITGAV signaling remains poorly understood. In our current study, we used in vitro experiments and 2 different in vivo models of myeloid cell-specific and macrophage-specific knockdown to investigate for the first time the role of αV integrin in regulation of infarct macrophage phenotype. We found that Itgav and its β chain partners Itgb1 and Itgb5 are highly expressed in subpopulations of infarct macrophages. In vivo, macrophage ITGAV did not play a significant role in repair and remodeling of the infarcted heart. Myeloid cell- and macrophage-specific ITGAV had no significant effects on inflammatory cell infiltration, myofibroblast accumulation, collagen deposition, angiogenesis, scar formation, dysfunction and remodeling after myocardial infarction. In vitro, ITGAV blockade had limited effects on the transcriptional profile of bone marrow macrophages. Importantly, the effects of fibronectin on expression of inflammatory, matrix remodeling and cell cycle genes by bone marrow macrophages were independent of ITGAV. In the healing infarct, macrophages exhibit dynamic phenotypic changes in response to microenvironmental alterations. Macrophages respond not only to cytokines and growth factors released in the infarcted heart, but also to the dynamic changes in the biochemical properties of the extracellular matrix network. During the inflammatory and proliferative phases of cardiac repair, deposition of a provisional matrix comprised of fibrin, fibronectin and a broad range of matricellular proteins forms a dynamic scaffold that facilitates cell migration, and provides important biochemical cues to drive cell differentiation and activation39. Communication between the cells and the components of the provisional matrix involves the integrins40. The αV integrins are broadly expressed in many different cell types, and recognize RGD peptides in a wide range of extracellular matrix proteins induced in the healing infarct, including fibronectin41 and vitronectin, and the matricellular proteins osteopontin42 and thrombospondin-143. Our experiments showed high expression of ITGAV mRNA and protein in significant subpopulations of infarct macrophages (Figs. 1–2). ScRNA-seq data showed that Itgav expression does not identify a specific cluster of macrophages but is expressed in subsets of macrophages from all clusters (Fig. 1). Increased expression of ITGAV in infarct macrophages may reflect actions of cytokines and growth factors (such as TGF-β and VEGF), which are capable of upregulating αv integrins in macrophages44 and in other cell types45. Despite evidence suggesting high ITGAV expression in macrophages in inflammatory and fibrotic conditions28,46, information on the in vivo role of macrophage ITGAV in homeostasis and disease is extremely limited. A study investigating the role of αV integrins in the immune system demonstrated that ~30% of the mice with myeloid cell-specific loss of ITGAV developed colonic inflammation at 40 weeks of age. Colitis in the absence of myeloid cell αV integrins was associated with impaired removal of apoptotic cells, perturbed generation of mucosal regulatory T cells, and high levels of autoantibodies34. There are no published data on the potential involvement of ITGAV in regulation of macrophage phenotype in tissue inflammation and repair. In our study we used 2 different Cre drivers to demonstrate that macrophage αV integrins do not play a significant role in repair and remodeling of the infarcted heart (Figs. 3–7). In the healing infarct, macrophages are known to be key cellular effectors in repair and scar formation2,47, serving as the main phagocytic cells that clear the infarct from dead cells and matrix debris11, and critically regulating inflammatory8,48,49, fibrogenic50,51,52,53,54,55, and angiogenic18,56,19, responses following infarction. However, macrophage infiltration, infarct angiogenesis, myofibroblast accumulation and collagen deposition in the infarcted heart were not affected by myeloid or macrophage-specific ITGAV loss. Thus, myeloid and macrophage-specific ITGAV signaling is dispensable for repair after myocardial infarction and does not play an important role in the pathogenesis of dysfunction and adverse remodeling. Published in vitro evidence suggest an important role for ITGAV in regulation of macrophage responses. ITGAV has been implicated in phagocytosis of apoptotic cells57 and may be involved in HIV infection of macrophages58. Moreover, in THP-1 monocyte/macrophages, integrin αvβ3 was found to mediate cell migration in response to IGF-159, and in a transwell assay, migration of bone marrow macrophages in response to periostin was dependent on ITGAV46. In vitro studies on the role of αV integrins in regulation of the inflammatory phenotype of macrophages have produced conflicting results. Some studies have suggested that αV integrins may inhibit macrophage pro-inflammatory activity by promoting M2 macrophage polarization in response to PPARγ activation30, while other investigations have suggested pro-inflammatory actions60,61, that may be mediated through NF-κB activation62. Our RNA-seq studies showed modest effects of ITGAV blockade on the macrophage transcriptome. Importantly, the pronounced effects of fibronectin on expression of inflammatory and cell cycle genes by macrophages were independent of ITGAV. The conflicting findings on the in vitro effects of αV integrins on macrophages may reflect contextual factors, such as the use of different αV integrin ligands, the stage of differentiation of the macrophages, and the presence or absence of additional macrophage-activating mediators. Our in vitro and in vivo findings suggest that macrophage ITGAV is not essential for repair and remodeling of the infarcted heart. Several mechanisms may account for the limited impact of macrophage ITGAV loss in the infarcted myocardium. First, fibronectin is a critical matrix signaling molecule in the infarcted heart, and contributes to fibrosis and adverse remodeling63,64. However, the effects of fibronectin on macrophages are largely ITGAV-independent (Fig. 8), limiting the consequences of macrophage-specific ITGAV loss. Second, extracellular matrix macromolecules that stimulate ITGAV signaling can also engage other integrins, including α5 and α8, which may compensate for the consequences of macrophage ITGAV loss. Third, infarct macrophages express low levels of Itgb3, Itgb6 and Itgb8, thus limiting the repertoire of ITGAV heterodimers available to modulate macrophage phenotype. Fourth, both scRNA-seq and immunofluorescence studies suggest that only ~20% of infarct macrophages express ITGAV, with cells dispersed across all clusters. This may dilute the effect of the integrin to a specific transcriptional program or functional phenotype. Fifth, our genetic loss-of-function approaches reduced but did not abolish macrophage ITGAV expression. Remaining ITGAV expression may be sufficient for activation of downstream signaling cascades, thereby preserving macrophage function. Despite its expression in a population of infarct macrophages, ITGAV does not play a significant role in repair, remodeling and fibrosis of the infarcted heart and does not mediate the effects of fibronectin on macrophages. In vivo studies have suggested that administration of αV integrin inhibitors, such as cilengitide, have anti-fibrotic effects in experimental models of myocardial infarction65,66. Our findings suggest that inhibition of fibrosis by αV inhibitors may predominantly involve actions on other cell types, such as interstitial fibroblasts, or vascular cells. Materials and methods Isolation, culture and stimulation of mouse Bone Marrow Macrophages (BMMs) Femoral and tibial BMMs were obtained from 2- to 3-month-old Wild-type C57BL/6 J mice, as previously described67. Briefly, bone marrow cells were incubated for 24 h in DMEM/F-12 medium (ThermoFisher) supplemented with 15% fetal bovine serum (GIBCO), and 12 ng/ml CSF-1 (R&D systems). Non-adherent primitive mononuclear phagocytes were reseeded in media containing 15% fetal bovine serum and CSF-1 (120 ng/ml) for 48 h, in order to allow their differentiation to adherent mononuclear phagocytes. The resulting adherent macrophages were passaged once into new plates. Cells used for experiments were cultured until confluent. To examine the effects of ITGAV signaling on macrophage phenotype, BMMs were cultured for 24 h in 60 mm petri dishes in the presence or absence of a blocking anti-ITGAV antibody (10 µg/ml, clone: RMV-7, Biolegend, 104110) or isotype matched IgG control (10 µg/ml, clone:RTK2071, Biolegend, 400432), with or without fibronectin pre-treatment (10ug/sample, Sigma, F1141). After 24 h of stimulation, RNA was harvested from the cells. RNA-seq was performed to explore the effects of ITGAV blockade on the transcriptomic profile of the macrophages, in the presence or absence of fibronectin. RNA extraction, and bulk RNA-seq Total RNA was extracted from bone marrow macrophages stimulated in the presence or absence of anti-ITGAV antibody by using QIAzol Lysis Reagent (Qiagen, 79306) and was used for RNA-seq analysis. RNA-seq was performed by Novogene (Sacramento, California). Library preparation for transcriptome sequencing RNA isolated from bone marrow macrophages stimulated in the presence or absence of anti-ITGAV antibody was used for RNA-sequencing. RNA was sent to Novogene (Sacramento, California) for the construction of a total of 16 cDNA libraries by using NEBNext® Ultra™ RNA Library Prep Kit for Illumina® (NEB, Ipswich, MA, USA). In brief, the process of library construction consisted of (i) mRNA purification and enrichment from total RNA using oligo(dt)-attached magnetic beads, (ii) fragmentation of purified mRNA using divalent cations exposed to elevated temperatures in NEBNext First Strand Synthesis Reaction Buffer, (iii) double stranded cDNA synthesis, using RNase H-reverse transcriptase (first strand) and DNA polymerase I, dNTP and RNase H (second strand); (iv) terminal cDNA ends reparation by exonucleases/polymerases; and poly adenylation of the 3’ ends of the DNA fragments, (v) Sequencing adapters ligation and finally (vi) cDNA fragments size selection (150–200 bp in length) which underwent PCR. PCR was performed using Phusion High-Fidelity DNA Polymerase, universal PCR primers and Index (X) Primer. PCR products were purified (AMPure XP system), and the library concentration (>2 nM) and quality were assessed using a Bioanalyzer 2100 system (Agilent, Santa Clara, CA, USA). Quality analysis, mapping and assembly The library preparations were sequenced on Illumina Novaseq X plus devices, generating 150 bp paired-end reads. Adapters, poly-N and low-quality reads from the raw data were excluded to purify the data analysis. Quality Phred Scores, Q20%, Q30% and GC contents of the clean data were calculated, showing high accuracy of reads (>99%, with 0.02 error rate). Filtered reads were aligned to the C57BL/6 J reference genome (Mus Musculus reference genome release December 2011 (mm10; GRCm38.p6) from Ensembl) using TopHat2 algorithm alignment program v.2.0.968. Mapped reads were assembled using both Scripture (beta2) and Cufflinks v.2.1.1 algorithm69. Gene expression, differential expression, enrichment and co-expression analysis HTSeq software v.0.6.170 was used to count the number of reads mapped to each gene. Read count of fragments per kilobase of transcript sequence per millions base pairs sequenced (FPKM) was used to calculate gene expression level, which considered the effects of both sequencing depth and gene length69. Read counts obtained from the gene expression analysis were used for differential expression analysis. Cluster differential expression analysis for every gene in the above different conditions was performed using the DESeq2 R software package (v.1.10.1)71. Genes with an adjusted P-value ≤ 0.05 were considered to be differentially expressed. The list of genes was ranked by differential gene expression as log2 (fold change) between each comparison group. Positive values were upregulated genes, whereas negative values were downregulated genes. Ingenuity pathway analysis (IPA) was used to identify the pathways which are regulated by αV integrin in macrophages. All RNA-seq processed data have been deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO SuperSeries accession number GSE190868. Generation of myeloid cell-specific and macrophage-specific ITGAV KO mice, breeding of macrophage reporter mice, animal management, and randomization The protocol for this study, including the research question, key design features, and analysis plan, was internally prepared prior to the commencement of the experiments and approved by the Institutional Animal Care and Use Committee (IACUC) at Albert Einstein College of Medicine. However, the protocol was not registered in a public database. All animals were housed in the Albert Einstein College of Medicine animal institute, a disease-free rodent facility. Animal care was in strict accordance with AAALAC and NIH guidelines. To study the role of αV integrin (ITGAV) in macrophages in vivo, we generated myeloid cell-specific and macrophage-specific ITGAV knockout mice. First, we used the lysozyme-M Cre driver (Jackson #004781))72. An effective and widely used tool for gene deletion in myeloid cells12 to generate myeloid cell-specific ITGAV KO mice (MyαVKO). LyzM-Cre mice were bred with ITGAV fl/fl (Jackson #032297) mice73 to generate LyzM-Cre;ITGAV fl/fl mice (MyαVKO) and ITGAV fl/fl littermates. Next, we used the CX3CR1-CreER driver (Jackson #020940)74 to generate mice with inducible loss of ITGAV in CX3CR1+ macrophages. CX3CR1-CreER mice were bred with ITGAV fl/fl animals to generate tamoxifen-inducible CX3CR1-CreER;ITGAV fl/fl mice (inducible macrophage-specific ITGAV knockouts, iMaαVKO) and corresponding ITGAV fl/fl control littermates. Tamoxifen (Sigma, T5648) was dissolved in 5% ethanol and 95% corn oil to make a 20 mg/mL stock solution. Tamoxifen was administered intraperitoneally every 24 h for 5 consecutive days (100 mg/kg/day) in iMaαVKO mice and corresponding ITGAV fl/fl animals. Mice were 10 weeks old during initiation of tamoxifen treatment. Two different tamoxifen dosing protocols were used: a) an early 5-day course of tamoxifen that was completed 7 days prior to MI, b) a dual course of tamoxifen, designed to optimally target macrophages recruited in the infarct from other sources (such as the bone marrow and the spleen), in which the early 5-day course is followed by a second 4-day course initiated after coronary occlusion (Supplementary Fig. 20). To study the time course of ITGAV activation in macrophages we used the “MacGreen” CSF1R-EGFP reporter mice75. These transgenic mice (Jackson labs #018549) express the enhanced green fluorescent protein (EGFP), under the control of the mouse Csf1r. 65 ITGAV fl/fl mice, 34 MyαVKO mice, 28 iMaαVKO mice and 29 CSF1R-EGFP reporter mice (both male and female) underwent non-reperfused myocardial infarction protocols. Mice enrolled in this study were categorized into ITGAV fl/fl, MyαVKO, and iMaαVKO groups based on their genotypes. These genotypic groupings were determined by genotyping performed after birth. To further minimize potential confounding factors and ensure experimental rigor, all mice undergoing MI surgery were randomly allocated to different housing cages during the post-operative recovery period and subsequent experimental phases. This was done to prevent systemic bias arising from cage effects or subtle environmental variations. All mouse cage locations were randomly arranged within the animal facility. During experimental procedures, such as cardiac tissue harvesting, echo, immunofluorescence staining, and image acquisition and quantitative analysis, measures were also taken to minimize potential bias. For instance, surgical procedures were performed by the same skilled investigator, and as many surgeries as possible were completed in the same batch to reduce batch effects. The order of immunofluorescence staining and image analysis was also randomized to prevent systemic bias introduced by factors such as investigator fatigue or variations in reagent batches. Mouse model of non-reperfused myocardial infarction We have complied with all relevant ethical regulations for animal use. Animal studies were approved by the Institutional Animal Care and Use Committee at Albert Einstein College of Medicine and conform with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health. A model of non-reperfused myocardial infarction was induced by permanent ligation of left anterior descending coronary artery, as previously described by our group12. ITGAV fl/fl mice, MyαVKO mice, iMaαVKO mice and CSF1REGFP mice were used for the in vivo study. 3-4-month-old male and female mice were anesthetized using inhaled isoflurane (3% for induction, 2% for maintenance). Intraoperatively, heart rate, respiratory rate and electrocardiogram were continuously monitored, and the depth of anesthesia was assessed using the toe pinch method. The left anterior descending coronary artery was occluded for 24 hours, 3 days, 7 days, or 28 days. To assess cardiac function and remodeling following myocardial infarction, animals underwent echocardiographic analysis at baseline and after 7 and 28 days of myocardial infarction. At the end of the experiment, euthanasia was performed using 2% inhaled isoflurane followed by cervical dislocation. Early euthanasia was performed with the following criteria, indicating suffering of the animal: weight loss>20%, vocalization, dehiscent wound, hypothermia, signs of heart failure (cyanosis, dyspnea, tachypnea), lack of movement, hunched back, ruffled coat, lack of food or water ingestion. At the end of the experiment, the animals were sacrificed, and the hearts and lungs were excised and weighed. Hearts were fixed in zinc-formalin (Z-fix, Anatech, Battle Creek, MI) and embedded in paraffin for histological studies (for myeloid cell and macrophage-specific ITGAVKO study, 7 days group: ITGAV fl/fl n = 18, MyαVKO n = 9, iMaαVKO n = 10; 28 days group: ITGAV fl/fl n = 21, MyαVKO n = 12, iMaαVKO n = 9; dual tamoxifen protocol: ITGAV fl/fl n = 5, iMaαVKO n = 6). CSF1REGFP mice were used for histological studies (control group: n = 6; 24 hours group: n = 6; 3 days group: n = 5; 7 days group: n = 6, 28 days group: n = 6). The surgical protocols were performed by an investigator blinded to the genotype of the animals. Echocardiography Echocardiographic studies were performed at baseline and after 7 and 28 days of permanent coronary occlusion to assess cardiac function and remodeling following myocardial infarction using the Vevo 2100 system (VisualSonics. Toronto ON). Baseline echocardiographic parameters were compared between male and female ITGAV fl/fl and MyαVKO (or iMaαVKO) mice at 4 months of age, and 7 and 28 days after myocardial infarction (baseline: ITGAV fl/fl n = 39, MyαVKO n = 21, iMaαVKO n = 18; 7-day group: ITGAV fl/fl n = 17, MyαVKO n = 9, iMaαVKO n = 10; 28-day group: ITGAV fl/fl n = 20, MyαVKO n = 12, iMaαVKO n = 8; dual tamoxifen protocol: baseline: ITGAV fl/fl n = 15; iMaαVKO n = 18. 7 days: ITGAV fl/fl n = 15; iMaαVKO n = 18. 28 days: ITGAV fl/fl n = 13; iMaαVKO n = 18). Long-axis B-mode was used to assess the geometric characteristics of the LV after myocardial infarction. Short-axis M-mode was used for measurement of systolic and diastolic ventricular and wall diameters. The left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular end-systolic volume (LVESV), and left ventricular end-diastolic volume (LVEDV) were measured as indicators of dilative remodeling. LV mass was measured as an indicator of hypertrophic remodeling. The echocardiographic off-line analysis was performed by an investigator blinded to the study groups. Quantitative morphometry and Artificial Intelligence (AI)-based assessment of collagen content For histopathological analysis, murine hearts were fixed in zinc-formalin (Z-fix; Anatech, Battle Creek, MI), and embedded in paraffin. Infarcted hearts were sectioned from base to apex at 600 µm intervals, thus reconstructing the whole heart, as previously described36. 20 sections (5 µm thick) were cut at each level. In order to assess scar size, the first section at each partition was stained with hematoxylin and eosin (H&E) (HE staining: for myeloid cell-specific ITGAVKO, 7 days group: ITGAV fl/fl n = 8, MyαVKO n = 9; 28 days group: ITGAV fl/fl n = 9, MyαVKO n = 11; for inducible macrophage-specific ITGAVKO study, 7 days group: ITGAV fl/fl n = 10, iMaαVKO n = 12; 28 days group: ITGAV fl/fl n = 11, iMaαvKO n = 9). Morphometric parameters were quantitatively assessed using Zen 2.6 Pro software (Carl Zeiss). The infarcted and non-infarcted areas were measured at each level and the volume of the infarct and of the non-infarcted remodeling myocardium at each level was calculated as: Infarct volume = infarct area x 600 µm (500 µm + 20 sections x 5 µm = 600 µm) and non-infarcted myocardium volume =non-infarcted area x 600 µm. The total volume of the infarcted and non-infarcted myocardium was calculated as the sum of the volumes of each partition. Scar size was measured by dividing the volume of the infarct by the total volume of the left ventricle (infarct volume + volume of non-infarcted myocardium) and was expressed as a percentage. Picrosirius red staining was used to label the collagen-based scar, and collagen content was quantitatively assessed in the infarct and remote myocardium using Intellesis and Image Analysis modules of Zen 2.6 Pro software. An artificial intelligence (AI) model was trained to segment and measure surface areas of collagen fibers. At least 10 different fields from two non-adjacent stained sections per mouse at 2 different levels (mid-myocardial, and apical levels) were scanned and analyzed per heart sample (Picrosirius red: 7 days group: ITGAV fl/fl n = 8, MyαVKO n = 9; 28 days group: ITGAV fl/fl n = 10, MyαVKO n = 11). Immunofluorescence and assessment of ITGAV expression, macrophage and myofibroblast density Immunofluorescence was used to study the time course of ITGAV localization in infarct macrophages and to assess the effects of myeloid and macrophage-specific ITGAV loss on macrophage and myofibroblast density and on the number of mature coated vessels. In order to study the time course of ITGAV activation in infarct macrophages, ITGAV (Abcam, ab179475) and GFP staining (Abcam, ab6662) was performed on sections from infarcted CSF1R-EGFP hearts at baseline, and after 24 h, 3 days, 7 days and 28 days of coronary occlusion (n = 6 for each timepoint). Quantitative analysis was performed by counting the number of ITGAV-positive and GFP-positive macrophages in 15 fields from 2 different sections from each animal. To assess the number of macrophages in the infarcted and remodeling myocardium, sections were stained with Mac-2 antibody (Cedarlane, CL8942AP) in the infarcted ITGAV fl/fl, MyαVKO and iMaαVKO (Mac-2 staining: in the myeloid cell-specific ITGAVKO study, 7 days group: ITGAV fl/fl n = 8, MyαVKO n = 9; 28-day group: ITGAV fl/fl n = 9, MyαVKO n = 10; in the inducible macrophage-specific ITGAVKO study, 7 days group: ITGAV fl/fl n = 10, iMaαVKO n = 12; 28 days group: ITGAV fl/fl n = 10, iMaαvKO n = 9). Macrophage quantitation was performed, using an AI model (Zen 2.6 Pro software) in which macrophages were identified as the DAPI-positive nuclei surrounded by Mac2+ profiles. To assess myofibroblast density, we performed immunofluorescent staining with an anti-α-SMA antibody (Sigma, F3777). Myofibroblasts were identified as spindle-shaped α-SMA-positive cells located outside the vascular media. An AI-based model (Zen 2.6 Pro software) was trained on multiple fields of different regions of the myocardium to identify myofibroblasts. Objects of interest were defined as the DAPI-positive nuclei surrounded by α-SMA profiles, excluding vascular smooth muscle cells. Quantitative analysis was performed using 10 fields from 2 different sections from each animal (α-SMA staining: in the myeloid cell-specific ITGAVKO study, 7 day group: ITGAV fl/fl n = 7, MyαVKO n = 9; 28-day group: ITGAV fl/fl n = 10, MyαVKO n = 12; in the inducible macrophage-specific ITGAVKO study, 7 days group: ITGAV fl/fl n = 10, iMaαVKO n = 12; 28 days group: ITGAV fl/fl n = 10, iMaαvKO n = 9). Negative controls were performed to confirm the specificity of the antibodies using sections in which the primary antibody was substituted by species-specific IgG at the same concentration. Quantitative histological studies were performed by investigators blinded to the study groups. Cell density was expressed as cells/mm2. Information on all the antibodies used in the study is provided in Supplementary Table 1. Analysis of scRNA-seq data Published scRNA-sequencing datasets of total interstitial cells from control and infarcted mouse hearts were analyzed35 (ArrayExpress database at EMBL-EBI under accession code E-MTAB-7376). Seurat v3.0 package in R was used to construct a Seurat object from gene expression matrices and metadata. Analysis of macrophage cluster-specific patterns of integrin expression in control mouse hearts and 3- and 7-day infarcts was performed. By default, differential expression testing in Seurat package is based on the non-parametric Wilcoxon rank sum test. The adjusted p-value was based on Bonferroni correction using all features in the dataset. Protein extraction and western blotting Protein from macrophages was extracted in RIPA lysis buffer (Thermofisher, 89900) along Halt™ Protease Inhibitor Cocktail (Thermofisher, 78429). Equal amount of protein from each experimental group was fractionated by 10% Mini-PROTEAN® TGX™ Gel (Bio-Rad Laboratories, 456-1036) and transferred onto a PVDF membrane (Bio-Rad Laboratories, 1620177). Membranes were incubated with anti-ITGAV (Abcam, ab179475) followed by the application of appropriate horse radish peroxidase (HRP)-conjugated secondary antibodies. Proteins were developed using Pierce™ ECL Western blot detection reagents (Thermofisher, 32106) and imaged by the ChemiDoc™ MP System (Bio-Rad Laboratories). Bands were densitometrically quantified by Image Lab 3.0 software (Bio-Rad Laboratories) and normalized to appropriate loading controls. Statistical analysis and reproducibility For all analyses, normal distribution was tested using the Shapiro-Wilk normality test. For comparisons of two groups unpaired two-tailed Student’s t test using (when appropriate) Welch’s correction for unequal variances was performed. The Mann-Whitney test was used for comparisons between two groups that did not show Gaussian distribution. For comparisons of multiple groups, one-way ANOVA was performed followed by Sidak’s multiple comparison test. The Brown-Forsythe test was used for comparisons between groups with significantly different standard deviations. The Kruskal–Wallis test, followed by Dunn’s multiple comparison posttest was used when one or more groups did not show Gaussian distribution. Survival analysis was performed using the Kaplan-Meier method. Mortality was compared using the log rank test. Data are expressed as means ± SEM. Statistical significance was set at P < 0.05. Sample sizes are provided in the sections describing the methodology for each experiment and in the figure legends. Datapoints represent independent biological replicates. Because the effects of macrophage-specific Itgav deletion on post-infarction cardiac remodeling and function were unknown, formal power calculations were not feasible. Therefore, sample size was determined based on our prior experience with similar mouse models of myocardial infarction19,76. In these studies, groups of 10–15 animals per genotype consistently provided sufficient power (~0.9 at α = 0.05) to detect biologically and statistically significant differences in cardiac geometric and functional parameters between experimental and control groups. Reporting summary Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article. Supplementary information Supplementary Information Description of Additional Supplementary files Supplementary Data 1 Reporting Summary Supplementary Information Description of Additional Supplementary files Supplementary Data 1 Reporting Summary